Published in PLoS One on July 10, 2015
Drug resistance in eukaryotic microorganisms. Nat Microbiol (2016) 1.00
Leishmaniasis worldwide and global estimates of its incidence. PLoS One (2012) 18.07
The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev (2008) 5.32
Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health (2001) 3.08
LeishVet guidelines for the practical management of canine leishmaniosis. Parasit Vectors (2011) 2.14
Combination therapy for visceral leishmaniasis. Lancet Infect Dis (2010) 1.96
Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem (2004) 1.86
Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J Immunol (2001) 1.73
Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug pentostam. J Biol Chem (2004) 1.60
Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol (2007) 1.50
Leishmania TDR1 structure, a unique trimeric glutathione transferase capable of deglutathionylation and antimonial prodrug activation. Proc Natl Acad Sci U S A (2012) 1.45
Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev (2009) 1.45
Elevated levels of polyamines and trypanothione resulting from overexpression of the ornithine decarboxylase gene in arsenite-resistant Leishmania. Mol Microbiol (1999) 1.40
Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania. Mol Microbiol (2005) 1.35
In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity. Antimicrob Agents Chemother (2008) 1.33
Antimonial-induced increase in intracellular Ca2+ through non-selective cation channels in the host and the parasite is responsible for apoptosis of intracellular Leishmania donovani amastigotes. J Biol Chem (2003) 1.32
Leishmania mexicana: energy metabolism of amastigotes and promastigotes. Exp Parasitol (1982) 1.30
N-myristoyltransferase from Leishmania donovani: structural and functional characterisation of a potential drug target for visceral leishmaniasis. J Mol Biol (2009) 1.28
Evaluation of the repeatability of ultra-performance liquid chromatography-TOF-MS for global metabolic profiling of human urine samples. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.22
Metabolomics to unveil and understand phenotypic diversity between pathogen populations. PLoS Negl Trop Dis (2010) 1.21
Modulation of gene expression in Leishmania drug resistant mutants as determined by targeted DNA microarrays. Nucleic Acids Res (2003) 1.16
Purine and pyrimidine metabolism in Leishmania. Adv Exp Med Biol (2008) 1.15
Gene expression regulation in trypanosomatids. Essays Biochem (2011) 1.11
Differences in energy metabolism between trypanosomatidae. Parasitol Today (1998) 1.08
Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1. Proc Natl Acad Sci U S A (2013) 1.07
Elevated levels of tryparedoxin peroxidase in antimony unresponsive Leishmania donovani field isolates. Mol Biochem Parasitol (2010) 1.05
Mechanism of metalloid-induced death in Leishmania spp.: role of iron, reactive oxygen species, Ca2+, and glutathione. Free Radic Biol Med (2006) 1.05
Roles of trypanothione S-transferase and tryparedoxin peroxidase in resistance to antimonials. Antimicrob Agents Chemother (2008) 1.04
Identification of a Leishmania infantum gene mediating resistance to miltefosine and SbIII. Int J Parasitol (2008) 1.02
Pentose phosphate metabolism in Leishmania mexicana. Mol Biochem Parasitol (2003) 1.01
The biosynthetic incorporation of the intact leucine skeleton into sterol by the trypanosomatid Leishmania mexicana. J Biol Chem (2001) 1.00
Low-molecular-mass antioxidants in parasites. Antioxid Redox Signal (2012) 0.99
Differential gene expression analysis in antimony-unresponsive Indian kala azar (visceral leishmaniasis) clinical isolates by DNA microarray. Parasitology (2007) 0.99
Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex. Infect Genet Evol (2011) 0.98
Lights and shadows on gene organization and regulation of gene expression in Leishmania. Front Biosci (Landmark Ed) (2011) 0.96
Two pathways for cysteine biosynthesis in Leishmania major. Biochem J (2009) 0.95
Induction of a stringent metabolic response in intracellular stages of Leishmania mexicana leads to increased dependence on mitochondrial metabolism. PLoS Pathog (2014) 0.95
Discovery of factors linked to antimony resistance in Leishmania panamensis through differential proteome analysis. Mol Biochem Parasitol (2012) 0.94
Proteome mapping of overexpressed membrane-enriched and cytosolic proteins in sodium antimony gluconate (SAG) resistant clinical isolate of Leishmania donovani. Br J Clin Pharmacol (2010) 0.93
Metabolic adaptations of Leishmania donovani in relation to differentiation, drug resistance, and drug pressure. Mol Microbiol (2013) 0.91
Comparative proteomic analysis of antimony-resistant and -susceptible Leishmania braziliensis and Leishmania infantum chagasi lines. Mol Biochem Parasitol (2013) 0.91
Purine salvage in Leishmania: complex or simple by design? Trends Parasitol (2012) 0.91
Meglumine antimonate directly increases phagocytosis, superoxide anion and TNF-alpha production, but only via TNF-alpha it indirectly increases nitric oxide production by phagocytes of healthy individuals, in vitro. Int Immunopharmacol (2008) 0.91
Leishmania panamensis infection and antimonial drugs modulate expression of macrophage drug transporters and metabolizing enzymes: impact on intracellular parasite survival. J Antimicrob Chemother (2013) 0.91
Drug resistance in vectorborne parasites: multiple actors and scenarios for an evolutionary arms race. FEMS Microbiol Rev (2013) 0.90
Differential expression of proteins in antimony-susceptible and -resistant isolates of Leishmania donovani. Mol Biochem Parasitol (2011) 0.90
Molecular characterization of the MRPA transporter and antimony uptake in four New World Leishmania spp. susceptible and resistant to antimony. Int J Parasitol Drugs Drug Resist (2013) 0.89
Proteomic and genomic analyses of antimony resistant Leishmania infantum mutant. PLoS One (2013) 0.89
Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis. Proc Natl Acad Sci U S A (2013) 0.89
Leishmania donovani amastigotes mobilize organic and inorganic osmolytes during regulatory volume decrease. J Eukaryot Microbiol (2005) 0.88
Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major. Antimicrob Agents Chemother (2011) 0.88
Structure, functions, and biosynthesis of glycoconjugates of Leishmania spp. cell surface. Biochemistry (Mosc) (2010) 0.87
Role of efflux pumps and intracellular thiols in natural antimony resistant isolates of Leishmania donovani. PLoS One (2013) 0.87
(Post-) Genomic approaches to tackle drug resistance in Leishmania. Parasitology (2013) 0.87
Untargeted metabolomic analysis of miltefosine action in Leishmania infantum reveals changes to the internal lipid metabolism. Int J Parasitol Drugs Drug Resist (2013) 0.86
Downregulation of mitogen-activated protein kinase 1 of Leishmania donovani field isolates is associated with antimony resistance. Antimicrob Agents Chemother (2011) 0.85
The potential of metabolomics for Leishmania research in the post-genomics era. Parasitology (2010) 0.85
Over-expression of 60s ribosomal L23a is associated with cellular proliferation in SAG resistant clinical isolates of Leishmania donovani. PLoS Negl Trop Dis (2013) 0.84
Genetic markers for SSG resistance in Leishmania donovani and SSG treatment failure in visceral leishmaniasis patients of the Indian subcontinent. J Infect Dis (2012) 0.84
Down regulation of KMP-11 in Leishmania infantum axenic antimony resistant amastigotes as revealed by a proteomic screen. Exp Parasitol (2009) 0.84
CE-ESI-MS metabolic fingerprinting of Leishmania resistance to antimony treatment. Electrophoresis (2012) 0.83
Metabolomic-based strategies for anti-parasite drug discovery. J Biomol Screen (2014) 0.82
Trypanothione: a unique bis-glutathionyl derivative in trypanosomatids. Biochim Biophys Acta (2013) 0.82
Transmission potential of antimony-resistant leishmania field isolates. Antimicrob Agents Chemother (2014) 0.81
Axenic Leishmania amazonensis promastigotes sense both the external and internal arginine pool distinctly regulating the two transporter-coding genes. PLoS One (2011) 0.81
Sphingolipids in parasitic protozoa. Adv Exp Med Biol (2010) 0.81
Exploring Leishmania major inositol phosphorylceramide synthase (LmjIPCS): insights into the ceramide binding domain. Org Biomol Chem (2011) 0.78
The trypanothione system and its implications in the therapy of trypanosomatid diseases. Int J Med Microbiol (2012) 0.78
Characterization of a methionine adenosyltransferase over-expressing strain in the trypanosomatid Leishmania donovani. Biochim Biophys Acta (2005) 0.78